The Lysine acetyl transferase PCAF/Kat2b in the control of glucose metabolism and insulin secretion
Event details
| Date | 06.05.2014 |
| Hour | 11:00 › 12:00 |
| Speaker | Dr. Jean-Sébastien Annicotte, CNRS, Lille (F) |
| Location | |
| Category | Conferences - Seminars |
SEMINAR of the LAUSANNE INTEGRATIVE METABOLISM and NUTRITION ALLIANCE (LIMNA)
Abstract:
Pancreatic β-cells control insulin secretion through a fine-tuned process. Dysfunctions of this particular cell type are at the origin of pathological conditions, such as Diabetes Mellitus. A common component of the two type of diabetes, i.e. immune type 1 and non-immune type 2 (T2D), is a decrease of β-cell function and/or mass, finally resulting in hyperglycemia and its subsequent deleterious consequences. Therefore, a complete understanding of the factors and mechanisms responsible for β-cell maintenance and function could be of interest for the treatment of diabetes.
The P300-CBP Associated Factor (PCAF/Kat2b) is a lysine acetyl transferase closely related to P300, CBP and GCN5. By using in vitro β-cell lines, Pcaf -/- global KO mice and human T2D islets, I will present data showing that PCAF is a key factor involved in the control of glucose metabolism through its direct role on insulin secretion. Global gene expression and ChIP-seq experiments reveal that PCAF controls a subset of target genes involved in the unfolded protein response/ER stress pathway. Our findings identify PCAF as a new player in type 2 diabetes physiopathology, and modulating its activity by pharmacological compound could represent an interesting therapeutic avenue for the treatment of T2D.
Bio:
PhD thesis at IGBMC, Strasbourg (F)
Postdoc at University of Montpellier and INSERM, Montpellier (F)
Current: Group Leader, Molecular Basis and Modelization of Diabetes and Obesity Laboratory, European Genomic Institute for Diabetes, CNRS UMR 8199, Lille (F)
Abstract:
Pancreatic β-cells control insulin secretion through a fine-tuned process. Dysfunctions of this particular cell type are at the origin of pathological conditions, such as Diabetes Mellitus. A common component of the two type of diabetes, i.e. immune type 1 and non-immune type 2 (T2D), is a decrease of β-cell function and/or mass, finally resulting in hyperglycemia and its subsequent deleterious consequences. Therefore, a complete understanding of the factors and mechanisms responsible for β-cell maintenance and function could be of interest for the treatment of diabetes.
The P300-CBP Associated Factor (PCAF/Kat2b) is a lysine acetyl transferase closely related to P300, CBP and GCN5. By using in vitro β-cell lines, Pcaf -/- global KO mice and human T2D islets, I will present data showing that PCAF is a key factor involved in the control of glucose metabolism through its direct role on insulin secretion. Global gene expression and ChIP-seq experiments reveal that PCAF controls a subset of target genes involved in the unfolded protein response/ER stress pathway. Our findings identify PCAF as a new player in type 2 diabetes physiopathology, and modulating its activity by pharmacological compound could represent an interesting therapeutic avenue for the treatment of T2D.
Bio:
PhD thesis at IGBMC, Strasbourg (F)
Postdoc at University of Montpellier and INSERM, Montpellier (F)
Current: Group Leader, Molecular Basis and Modelization of Diabetes and Obesity Laboratory, European Genomic Institute for Diabetes, CNRS UMR 8199, Lille (F)
Practical information
- Informed public
- Free
Organizer
- Kristina Schoonjans and Johan Auwerx (for the LIMNA Alliance)
Contact
- Johan Auwerx / Kristina Schoonjans
------------------
(*) IMPORTANT NOTICE : All external participants have to pass through SV Reception/Welcome Desk to be able to access to AI 1153. Contact person to call upon arrival at SV Reception Desk: Johan Auwerx 30951 / Administrative Assistant: 39522.